Gastric Cancer Diagnostic Procedure Market Outlook 2034

The gastric cancer diagnostic procedure market size is expected to reach US$ 2.69 billion by 2034 from US$ 1.53 billion in 2025. The market is anticipated to register a CAGR of 6.53% during 2026–2034.

Gastric Cancer Diagnostic Procedure Market Analysis

The Gastric Cancer Diagnostics market is experiencing rapid expansion due to the rising global incidence of gastric cancer. This growth is further fueled by the increasing emphasis on early detection and screening programs and significant advancements in diagnostic technologies. Technologies such as molecular diagnostics, advanced imaging, and non-invasive methods like liquid biopsy are becoming increasingly integral for personalized treatment plans. The market is shifting towards precision medicine, which relies heavily on advanced diagnostic tools to identify specific biomarkers (e.g., HER2, PD-L1) for targeted therapies. The market is expected to grow rapidly with the continuous development of novel biomarkers and the expansion of diagnostic services into specialized laboratories and hospitals.

Gastric Cancer Diagnostic Procedure Market Overview

The implementation of advanced diagnostic procedures in gastric cancer is crucial for early detection, accurate staging, and guiding personalized therapeutic strategies. Procedures range from traditional methods like endoscopy with biopsy and imaging tests (CT, MRI) to advanced molecular diagnostics and liquid biopsies. These tools provide critical information on the tumor's genetic and molecular profile, allowing clinicians to tailor treatments for improved patient outcomes. The market is highly influenced by the high prevalence of Adenocarcinoma, the most common type of gastric cancer. There is a continuous drive to develop more cost-effective and non-invasive diagnostic solutions to improve patient access, especially in high-risk populations and developing regions.

Gastric Cancer Diagnostic Procedure Market: Strategic Insights

Gastric Cancer Diagnostic Procedure Market Drivers and Opportunities

Market Drivers:

• Increasing Global Incidence of Gastric Cancer: The rising prevalence of gastric cancer, often linked to an aging population, lifestyle factors (smoking, alcohol use), and Helicobacter pylori infection, is the primary driver for increased demand for diagnostic tools.
• Advancements in Diagnostic Technologies: Innovations like AI-powered endoscopy, liquid biopsy, and the integration of Next-Generation Sequencing (NGS) for molecular profiling are enhancing the accuracy and efficiency of detection.
• Growing Focus on Early Detection and Screening: Government and healthcare organizations worldwide are implementing screening programs, particularly in high-incidence areas, to detect gastric cancer at earlier, more treatable stages.

Market Opportunities:

• Growth in Personalized Medicine: The shift toward tailored treatment plans based on individual patient genetic and molecular profiles creates a massive opportunity for manufacturers of advanced biomarker tests and companion diagnostics (e.g., tests for HER2, PD-L1).
• Development of Non-Invasive Diagnostics: The push for non-invasive methods, such as liquid biopsies (using blood, urine, or saliva), offers a less painful and more scalable approach for screening and monitoring, opening new avenues for market entry.
• Expansion of Telemedicine Services: The growing adoption of telemedicine, particularly for follow-up and remote consultation, provides an opportunity to enhance access to diagnostic evaluations for patients in remote or underserved areas.

Gastric Cancer Diagnostic Procedure Market Report Segmentation Analysis

The Gastric Cancer Diagnostics Market share is analyzed across various segments to provide a clearer understanding of its structure, growth potential, and emerging trends.

By Healthcare Provider:

• Diagnostic Laboratories
• Hospitals
• Cancer Research Institutes
• Oncology Specialty Clinics

By Symptom Type:

• Symptomatic
• Asymptomatic

By Body Fluid:

• Blood
• Urine
• Saliva
• Stomach Wash/Gastric Juice
• Tissue

By Procedure:

• Endoscopic Procedures
• Biopsy & Tissue Tests
• Lab Tests
• In-Vitro Diagnostic Tests
• Imaging Tests
• Molecular Diagnostics
• Multiplexing Molecular Diagnostics & Immunoassays

By Geography:

• North America
• Europe
• Asia-Pacific
• South & Central America
• Middle East & Africa

Gastric Cancer Diagnostic Procedure Market Players Density: Understanding Its Impact on Business Dynamics

The Gastric Cancer Diagnostic Procedure Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Gastric Cancer Diagnostic Procedure Market Share Analysis by Geography

North America holds the largest market share, driven by a robust and advanced healthcare infrastructure, high adoption of precision medicine, and the presence of key industry players. Asia-Pacific is anticipated to be the fastest-growing regional market due to the highest incidence rates of gastric cancer, a large and aging population, and improving healthcare investment.

North America

• Market Share: Holds the largest market share, driven by sophisticated healthcare systems and high technology adoption.
• Key Drivers: High adoption of advanced diagnostic technologies (liquid biopsy, NGS), presence of leading diagnostics companies, and a strong focus on personalized medicine.
• Trends: Increasing use of molecular profiling and companion diagnostics for targeted therapy selection.

Europe

• Market Share: Significant market share, supported by well-established healthcare systems.
• Key Drivers: Strong regulatory framework and public-private collaborations to improve cancer care.
• Trends: Focus on high-quality, standardized diagnostic practices and increasing investment in R&D for novel biomarkers.

Asia Pacific

• Market Share: The fastest-growing regional market, driven by high disease burden.
• Key Drivers: Highest incidence of gastric cancer globally, government-backed initiatives for cancer screening, and expanding healthcare infrastructure.
• Trends: Mass screening programs in high-risk areas and rapid adoption of advanced digital diagnostic tools.

South and Central America

• Market Share: Emerging region with growing adoption.
• Key Drivers: Increasing awareness of gastric cancer risk factors and improving digital infrastructure supporting diagnostic platforms.
• Trends: Expansion of affordable diagnostic solutions by global tech providers and rising digital adoption in healthcare.

Middle East and Africa

• Market Share: Emerging market with strong growth potential.
• Key Drivers: Major national digital transformation strategies in countries like the UAE and Saudi Arabia, and increasing investment in specialized cancer centers.
• Trends: Implementation of specialized diagnostic services and integration of basic molecular testing.

Gastric Cancer Diagnostic Procedure Market Players Density: Understanding Its Impact on Business Dynamics

The Gastric Cancer Diagnostics Market is highly competitive, featuring established global pharmaceutical and diagnostics companies alongside specialized biotechnology firms and molecular diagnostics startups. Competition centers around innovation in achieving earlier, more accurate, and less invasive detection.

The competitive landscape is driving vendors to differentiate through:

• Developing cutting-edge technologies like AI for image analysis (endoscopy, pathology) and liquid biopsy assays to offer non-invasive and highly sensitive tests.
• Intense R&D efforts to discover and commercialize new biomarkers and the companion diagnostics required for targeted therapies.
• Collaborations between diagnostic companies and pharmaceutical firms to co-develop diagnostic tests alongside new cancer drugs, ensuring seamless patient selection for specific treatments.

Opportunities and Strategic Moves

• Personalized Diagnostics: Leveraging advanced genomic and proteomic platforms to provide a comprehensive profile of a patient’s tumor, opening new revenue streams through highly specialized, high-value testing.
• Mergers and Acquisitions (M&A): Large players acquire smaller biotech and diagnostics startups to quickly integrate novel technologies (like liquid biopsy or AI algorithms) into their existing portfolios.
• Global Expansion: Focusing on high-incidence regions, particularly Asia-Pacific, by establishing local distribution networks and obtaining regional regulatory approvals to capitalize on high demand.

Major Companies Operating in the Gastric Cancer Diagnostic Procedure Market Are:

1. Atlas-Link Biotech Co Ltd
2. Bio-Rad Laboratories Inc
3. MiRXES Pte Ltd
4. Agilent Technologies Inc
5. F. Hoffmann-La Roche Ltd
6. bioMerieux SA
7. Thermo Fisher Scientific Inc
8. Illumina Inc
9. Vela Diagnostics Holding Pte Ltd

Disclaimer: The companies listed above are not ranked in any particular order.

Gastric Cancer Diagnostic Procedure Market News and Recent Developments

• For instance, on October 09, 2025, Mirxes, a leading and only publicly-listed molecular cancer early detection company in Asia Pacific, announced that its flagship product, GASTROClear™, has been granted regulatory approval by China’s National Medical Products Administration (NMPA) as an in vitro diagnostic (IVD) product, becoming the first non-invasive blood test approved for the screening of gastric cancer in China.
• On April 17, 2025, Agilent Technologies Inc. announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by Merck.
• In October 2024, Roche received FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY.

Gastric Cancer Diagnostic Procedure Market Report Coverage and Deliverables

The "Gastric Cancer Diagnostics Procedure Market Size and Forecast (2021–2034)" report provides a detailed analysis of the market covering below areas:

• Gastric Cancer Diagnostics Procedure Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Gastric Cancer Diagnostics Procedure Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Gastric Cancer Diagnostics Procedure Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Gastric Cancer Diagnostics Procedure Market. Detailed company profiles.